VILAS Ventures invested in a $13.5m Series A round in CND Life Sciences.

VILAS Ventures, a healthcare-focused investment firm, invested in a $13.5m Series A round in CND Life Sciences, a diagnostics company developing innovative tools for the detection of neurodegenerative diseases, with participation from Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital, BlueStone Ventures, Labcorp and MBX Capital. "Neurodegenerative diseases remain among the most urgent unmet needs in medicine. CND’s Syn-One Test combines cutting-edge pathology and AI to provide objective diagnostic clarity for clinicians and biopharma companies alike. We are thrilled to support their mission at such a critical inflection point," Daniel Livschutz, VILAS Ventures Managing Partner.